The depot paradox

Behavioral Healthcare

Volumn 27, Issue 5, 2007, Pages 44-46

  Glazer, William M ^a,b,c,d,e  

^a Glazer Medical Solutions   (United States)

^b Glazer Medical Solutions   (United States)

^c AstraZeneca ^*

^d ELI LILLY AND COMPANY   (United States)

^e ReliaLAB Inc

Author keywords

[No Author keywords available]

Indexed keywords

NEUROLEPTIC AGENT;

DELAYED RELEASE FORMULATION; DRUG UTILIZATION; EVIDENCE BASED MEDICINE; HEALTH PERSONNEL ATTITUDE; HUMAN; INJECTION; ORAL DRUG ADMINISTRATION; PATIENT COMPLIANCE; REVIEW; RISK ASSESSMENT; UNITED STATES;

ADMINISTRATION, ORAL; ANTIPSYCHOTIC AGENTS; ATTITUDE OF HEALTH PERSONNEL; DELAYED-ACTION PREPARATIONS; DRUG UTILIZATION; EVIDENCE-BASED MEDICINE; HUMANS; INJECTIONS; PATIENT COMPLIANCE; RISK ASSESSMENT; UNITED STATES;

EID: 34249778381     PISSN: 19317093     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (14)

1. National Alliance on Mental Illness. Grading the States: A Report on America's Health Care System for Serious Mental Illness. Arlington, Va.: NAMI; 2006. www.nami.org/Content/ NavigationMenu/Grading_the_States/Full_ Report/GTS06_final.pdf.
2. McGorry PD. Translating advances in schizophrenia treatment: A glass ceiling. Med J Aust 2003;178(9):425-6.
3. Marder SR. Depot neuroleptics: Side effects and safety. J Clin Psychopharmacol 1986;6(1 Suppl):24S-29S.
4. Lacro JP, Dunn LB, Dolder CR, et al. Prevalence of and risk factots for medication nonadherence in patients with schizophrenia: Acomprehensive review of recent literature. J Clin Psychiatry 2002;63(10):892-909.
5. Hudson TJ, Owen RR, Thtush CR, et al. A pilot study of barriers to medication adherence in schizophrenia. J Clin Psychiatry 2004; 65(2):211-16.
6. Weiden PJ, Olfson M. Cost of relapse in schizophrenia. Schizophr Bull 1995;21(3):419-29.
7. Adams CE, Fenton MK, Quraishi S, David AS. Systematic meta-review of depot antipsychotic drugs for people with schizophrenia. Br J Psychiatry 2001;179:290-9.
8. Heres S, Hamann J, Kissling W, Leucht S. Attitudes of psychiatrists toward antipsychotic depot medication. J Clin Psychiatry 2006;67(12): 1948-53.
9. Glazer WM, Kane JM. Depot neuroleptic therapy: An underutilized treatment option. J Clin Psychiatry 1992;53(12):426-33.
10. Shi L, Ascher-Svanum H, Zhu B, et al. Characteristics and use patterns of patients taking first-generation depot antipsychotics of oral antipsychoticsforschizophrenia. PsychiatrServ 2007;58(4):482-8.
11. Glazer WM. Who receives long-acting antipsychotic medications? Psychiatr Serv 2007;58 (4):437.
12. Glazer WM. Fluphenazine decanoate. Its steady-state pharmacologie profile and relationship to tardive dyskinesia. Schizophr Res 1988;1(6):425-9.
13. Patel MX, David AS. Why aren't depot antipsychotics prescribed more often and what can be done about it? Advances in Psychiatric Treatment 2005;11:203-11.
14. Heinssen RK. Improving medication compliance of a patient with schizophrenia through collaborative behavioral therapy. Psychiatr Serv 2002;53(3):255-7.